1 Multi-ancestry GWAS of Long COVID identifies

² immune-related loci and etiological links to chronic fatigue

syndrome, fibromyalgia and depression

4 Authors: Ninad S. Chaudhary, Catherine H. Weldon, Priyanka Nandakumar, 23andMe

5 Research Team, Michael V. Holmes* and Stella Aslibekyan*

⁶ *co-senior authors

- 7 Institution: 23andMe, Inc
- 8

3

- 9
- Ĩ.

10

.

11

12

13 Corresponding Author:

14 Stella Aslibekyan PhD

15 23andMe. Inc

1 ABSTRACT

² The etiology of Long COVID is poorly understood despite its estimated global burden of 3 65 million cases. There exists a paucity of genetic studies that can shed light on 4 potential mechanisms leading to Long COVID. Using consented and genotyped data 5 from 23andMe adult research participants, we conducted the largest multi-ancestry 6 meta-analysis of genome-wide association studies of Long COVID across European 7 (42,899 cases, 94,721 controls), Latinx (8,631 cases, 20,351 controls), and 8 African-American (2,234 cases, 5,596 controls) genetic ancestry groups. GWAS of Long 9 COVID identified three genome-wide significant loci (HLA-DQA1-HLA-DQB, ABO, 10 BPTF-KPAN2-C17orf58). Functional analysis of these genes points to underlying 11 immune and thrombo-inflammatory mechanisms. We present evidence of shared 12 genetic architecture (genetic correlation p-value < 0.001) of Long COVID with thirteen 13 phenotypes of similar symptomatology or pathophysiology. We identified potential 14 causal roles from liability to chronic fatigue (Mendelian randomization OR=1.59, 95% 15 CI[1.51,1.66]), fibromyalgia (OR=1.54, 95% CI[1.49,1.60]), and depression (OR=1.53, 16 95% CI[1.46,1.61]) with Long COVID, which replicated in the COVID-19 Host Genetics 17 Initiative data, and which are unlikely to originate from collider bias. These findings can 18 help identify populations vulnerable to Long COVID and inform future therapeutic 19 approaches.

20

1 INTRODUCTION

² Long COVID (post-acute sequelae of SARS-CoV2-infection or post-acute COVID-19
³ syndrome) is a debilitating condition characterized by symptoms persisting for months
⁴ following the acute infection. Since the global spread of SARS-CoV2, more than 65
⁵ million people have reported experiencing symptoms that can be classified as Long
⁶ COVID (Davis et al. 2023). It is estimated that 7.3% of SARS-CoV2 positive individuals
⁷ and 52% of those hospitalized due to COVID-19 in the US (Robertson et al. 2023;
⁸ Taquet et al. 2021; O'Mahoney et al. 2023) subsequently develop Long COVID.
⁹ Individuals experiencing Long COVID predominantly report fatigue, cognitive
¹⁰ impairment and breathlessness impacting daily activities (O'Mahoney et al. 2023; Ford
¹¹ et al. 2024; Lopez-Leon et al. 2021).

12

¹³ Vaccination efforts have been shown to reduce the risk of developing Long COVID
¹⁴ symptoms in SARS-CoV2 positive individuals (Català et al. 2024; Robertson et al.
¹⁵ 2023). However, among individuals with Long COVID, it is not clear whether vaccination
¹⁶ attenuates symptoms, making it imperative to continue identifying treatment options for
¹⁷ Long COVID (Notarte et al. 2022; Tran et al. 2023). NIH-funded clinical trials are
¹⁸ underway for exploring the efficacy of Paxlovid for the treatment of Long COVID. This
¹⁹ represents just one potential therapeutic strategy: lack of knowledge of the underlying
²⁰ etiological mechanisms represents an ongoing challenge to developing evidence-based
²¹ treatment options.

22

1 Genome-wide association studies (GWAS) of acute COVID-19 susceptibility and 2 severity have contributed in establishing the role of immune mechanisms in response to 3 acute SARS-CoV2 infection (Shelton et al. 2021; COVID-19 Host Genetics Initiative 4 2023). In contrast, the genetic evidence identifying biological mechanisms in Long 5 COVID is limited (Ledford 2024). Mechanisms that can lead to Long COVID may 6 include persistence of viral burden, autoimmune response, and inflammation. A recent 7 GWAS of Long COVID by the COVID-19 Host Genetics Initiative (HGI) identified a 8 single risk locus (FOXP4 gene) for Long COVID at chromosome 6 (Lammi et al. 2023). 9 This locus has previously been linked to acute COVID-19 susceptibility and severity 10 (COVID-19 Host Genetics Initiative 2023), recognised risk factors for Long COVID 11 (Whitaker et al. 2022). However, the mechanisms underlying the FOXP4 genetic signal, 12 postulated to include lung function, explain only a part of the multi-systemic response 13 that is postulated to occur in Long COVID. Overall, the mechanistic understanding of 14 Long COVID continues to be elusive. Larger-scale GWAS of Long COVID restricted to 15 previously COVID-19 infected individuals are well suited to identifying genetic loci 16 conferring risk of Long COVID, while controlling for susceptibility, and may help inform 17 treatment strategies.

18

¹⁹ Epidemiological studies have also identified similarities between phenotypic clusters of
²⁰ Long COVID and other post-viral syndromes and chronic conditions. (Sherif et al. 2023;
²¹ Davis et al. 2023; Thompson et al. 2023). This posits the question of whether a
²² pre-existing chronic condition can increase the risk of developing Long COVID. By
²³ leveraging GWAS data on these conditions, we can further elucidate disease etiology to

1 identify putative causal risk factors that may shed light on mechanistic pathways. The
2 23andMe research cohort provides an opportunity to investigate the genetic architecture
3 of Long COVID and to conduct post-GWAS translational studies such as Mendelian
4 randomization to shed light on potential etiology. Accordingly, using ancestrally-diverse
5 data from the 23andMe database, we conducted GWAS in three ancestries and
6 performed meta-analysis to identify genetic variants associated with Long COVID in a
7 cohort of COVID-19 infected individuals. We further investigated genetic correlations
8 between Long COVID and symptomatologically similar phenotypes and explored their
9 potential causal relevance, including the role of acute COVID-19 severity, through
10 Mendelian randomization.

11

12 METHODS

13 Study population and data collection

¹⁴ Details of the 23andMe Research Cohort have been previously described (Shelton et al.
¹⁵ 2021). Self-reported data were obtained from online survey questionnaires on
¹⁶ demographics, socio-behavioral characteristics, and health conditions. Data on Long
¹⁷ COVID were collected through a survey designed to inform about the symptomatic
¹⁸ burden and impact on daily living activities. Participants who had previously reported to
¹⁹ have COVID-19 diagnosis or tested positive for SARS-CoV2 were invited via email to
²⁰ participate in the Long COVID survey. Additional respondent characteristics, such as
²¹ age, sex, pre-existing conditions (high blood pressure, diabetes, chronic kidney disease,
²² coronary heart disease, cardiac arrhythmias, high cholesterol, history of blood clots, and
²³ chronic obstructive pulmonary disease), educational attainment, smoking status were

1 queried in the baseline COVID-19 surveys if the data were missing from previously
2 distributed health surveys. Data collected between August 2021 and February 2024
3 were used for the current work (Figure 1).

4

5 Data availability

⁶ The full GWAS summary statistics for the 23andMe discovery data set will be made

7 available through 23andMe to qualified researchers under an agreement with 23andMe

8 that protects the privacy of the 23andMe participants. Datasets will be made available at

9 no cost for academic use. Please visit

10 https://research.23andme.com/collaborate/#dataset-access/ for more information and to11 apply to access the data.

12

13 Ethics statement

- 14 Study participants provided informed consent. The recruitment, informed consent, and
- 15 collection of online data via surveys were conducted according to our human
- 16 participants research protocol, which was reviewed and approved by Ethical and
- 17 Independent Review Services, a private institutional review board

18 (http://www.eandirreview.com). As of 2022, E&I Review Services is part of Salus IRB

19 (https://www.versiticlinicaltrials.org/salusirb).

20 Phenotype definition

21 In contrast to prior Long COVID GWAS using population controls (Lammi et al. 2023),

22 only participants who were diagnosed with COVID-19 or had tested positive for

23 COVID-19 were included in the main analysis. We first excluded those who had

1 reported to have had acute COVID-19 illness within the last three months for 2 consistency with the widely accepted definition whereby to be eligible to be a Long 3 COVID case, it occurred three months after the acute infection (Soriano et al. 2022). 4 Long COVID was defined using self-reported data on the question: "Have you 5 experienced post-acute COVID-19 syndrome (also called 'Long COVID' or 'Long 6 Haulers')?". Those who responded "yes" to the question were defined as cases of Long 7 COVID. Participants who responded "No" to the question were defined as controls. 8 The data on impact on daily life activities were obtained among individuals who reported 9 having a COVID-19 diagnosis and symptoms lasting for one month or longer since 10 illness from the question "On average, how much has your persistent COVID-19 11 symptoms impacted your normal activities? If you have fully recovered, please respond 12 based on your experience before you fully recovered". Participants' responses were 13 recorded on a 5 point Likert scale of "not at all, slightly, moderately, quite a bit, 14 extremely". Among controls, 16,390 individuals had responded to having some impact 15 on daily activities post acute illness and were excluded from this group. In a sensitivity 16 analysis, we modified the definition for Long COVID cases incorporating the impact of 17 Long COVID symptoms on daily life (referred to as "Long COVID Impact" phenotype) 18 (Lammi et al. 2023; Soriano et al. 2022). Long COVID Impact phenotype was defined as 19 those who self-reported Long COVID, and had moderate to severe impact of Long 20 COVID symptoms on daily living activities. The impact was considered moderate to 21 severe if participants chose the following answer options: moderately, quite a bit, or 22 extremely (N=32,346).

23

1 Genotyping

2 DNA extraction and genotyping were performed on saliva samples by Clinical 3 Laboratory Improvement Amendments and Collage of American Pathologists-accredited 4 clinical laboratories of Laboratory Corporation of America. The details of genotyping 5 platforms and imputation guality controls have been previously described (Chaudhary et 6 al. 2024). Approximately 110 million variants were available for genome-wide analyses 7 after the quality control procedures. Genotyped data were further analyzed to determine 8 the ancestry of the participants using a genetic ancestry classification algorithm. 9 Subsequent analyses were performed separately for each ancestry. To limit our 10 analyses to unrelated individuals, we selected participants such that no two individuals 11 shared more than 700cM of DNA identical by descent. In a scenario where a case and a 12 control have at least 700cM of DNA identical by descent, we removed the control from 13 the analytical sample. After excluding unrelated individuals while prioritizing the 14 retention of cases, the analytical cohort for GWAS consisted of 53,764 cases and 15 120,688 controls for Long COVID, and 32,087 cases and 121,298 controls for Long 16 COVID Impact.

17

18 Imputation of classical HLA Alleles

¹⁹ Imputation of *HLA* alleles was performed using the HIBAG13 R package (Zheng et al.
²⁰ 2014). HIBAG is an attribute bagging based statistical method that uses a pre-fit
²¹ classifier to impute the allelic dosages of *HLA* alleles. This classifier was trained from a
²² large internal database of individuals with known *HLA* alleles and SNP variation within
²³ the HLA region. We used the default setting of HIBAG and used a multi-population

1 reference panel from 100,000 samples of 23andMe internal data and other external
2 data. Approximately 98% of the tagging SNPs used in HIBAG were genotyped and
3 passed quality control on 23andMe's platform. We imputed allelic dosage for *HLA-A*, *B*,
4 *C*, *DPA1*, *DPB1*, *DQA1*, *DQB1* and *DRB1* loci at the p-group resolution where *HLA*5 alleles that encode the same protein sequence for the peptide binding domains (exon 2
6 and 3 for class I and exon 2 only for class 2) are grouped together and designated with
7 4 digits (Tian et al. 2017). Similar to SNP imputation, we measured imputation quality
8 using r² which ranged from 0.72 to 1.00. Overall, there were 855 imputed classical HLA
9 alleles at four-digit resolution available for analysis.

10

11 Ancestry determination

12 Ancestries in the 23andMe database are determined using a classifier algorithm based 13 on analysis of local ancestry (Durand et al. 2014). Phased genotyped data were first 14 partitioned into windows of about 300 SNPs and a support vector machine (SVM) 15 approach was applied within each window to classify individual haplotypes into one of 16 45 worldwide reference populations. The SVM classifications are then fed into a hidden 17 Markov model (HMM) that accounts for switch errors and incorrect assignments, and 18 gives probabilities for each reference population in each window. Finally, we used 19 simulated admixed individuals to recalibrate the HMM probabilities so that the reported 20 assignments are consistent with the simulated admixture proportions. We aggregated 21 the probabilities of the 45 reference populations into six main ancestry categories 22 (European, African-American, Latinx, East Asian, South Asian, Middle Eastern) using a 23 predetermined threshold (Durand et al. 2014). African Americans and Latinx were admixed with broadly varying contributions from Europe, Africa and the Americas. No
single threshold of genome-wide ancestry could effectively discriminate between African
Americans and Latinx. However, the distributions of the length of segments of
European, African and American ancestry are very different between African Americans
and Latinx, because of distinct admixture timing between the three ancestral
populations in the two ethnic groups. Therefore, we trained a logistic classifier that took
the participant's length histogram of segments of African, European and American
ancestry, and predicted whether the customer is likely African American or Latinx.

9

10 STATISTICAL ANALYSIS

11 Multi-ancestral GWAS

¹² Within each ancestral group, we performed logistic regression for Long COVID with ¹³ additive allelic effects for each variant. The model was adjusted for age, age-squared, ¹⁴ sex, and the top five within-ancestry principal components to account for residual ¹⁵ population structure and genotyping platform. The genome-wide threshold for significant ¹⁶ association for each variant was < 5.0 X 10⁻⁸. The summary statistics were corrected for ¹⁷ inflation using genomic control when the inflation factor was greater than one and ¹⁸ presented using Manhattan plots. We then constructed regions of significant association ¹⁹ by identifying all SNPs with P < 10⁻⁵ within the vicinity of a genome-wide significant ²⁰ association. We defined a distance between neighboring regions of association of at ²¹ least 250kb to identify a significant locus. The SNP with the smallest P-value within ²² each region was identified as the index variant. We also calculated a credible set of ²³ variants within each region based on Bayesian approach to refine the association 1 signals (Wellcome Trust Case Control Consortium et al. 2012). The regional LD plots for
2 each index variant were constructed. The analyses were conducted separately in each
3 genetic ancestry cohort (Europeans, African-Americans, and Latinx). Participants
4 classified as other ancestral groups (South Asian, East Asian, and Middle Eastern) were
5 excluded due to insufficient GWAS sample size. We also conducted logistic regression
6 between *HLA* loci and Long COVID adjusting for above mentioned covariates. Previous
7 studies have shown that *HLA* imputed alleles are associated with viral infections as
8 individuals carrying the same *HLA* allelic dosage recognize the same viral epitope (Tian
9 et al. 2017; Augusto et al. 2023; Debebe et al. 2020). We accordingly determined the
10 associations between *HLA* alleles imputed till four-digit resolution and Long COVID by
11 ancestry in the region of statistically significant *HLA* loci.

12

13 Meta-Analysis

We then performed a multi-ancestry meta-analysis of above GWAS using the inverse variance fixed effect model. Only variants with minor allele frequency of more than one percent in all ancestries were considered for meta-analysis. The associations were further adjusted for inflation and tested for heterogeneity between genetic ancestry using the Cochran's Q test. The effect estimates of index variants on meta-analyses are presented as odds ratios (OR) on an additive allelic scale.

20

21 Functional annotation of GWAS index variants

22 To perform variant-to-gene mapping, hypotheses of functionally relevant genes are23 generated by annotating the index variants. Functional variants for mapping include

1 coding variants (annotated by the Ensembl Variant Effect Predictor (VEP) v109 44),
2 eQTLs, and pQTLs. The eQTL annotation resources consist of a comprehensive
3 collection of standardized variants impacting gene expression in various tissues
4 obtained from publicly available datasets (GTEx Consortium 2020; Qiu et al. 2018;
5 Kettunen et al. 2012; Franzén et al. 2016; Raj et al. 2014; Kerimov et al. 2021;
6 Lappalainen et al. 2013; Koolpe et al. 1985; Craig et al. 2021) and datasets processed
7 by the 23andMe eQTL pipeline. The pQTL annotation resources similarly include a
8 collection of curated protein QTLs from relevant public datasets (Zhang et al. 2022;

9 Ferkingstad et al. 2021).

a eQTL calling was performed with one of two versions of 23andMe pipelines, depending
a on the dataset in question (Supplementary File). The first pipeline used FastQTL
(Ongen et al. 2016) in permutation mode, restricting all tests to variants within a
window defined to be 1Mbp up- or downstream of a given gene's transcription start site
(TSS) (Supplementary File Table 1). Variants tested were single nucleotide
polymorphisms with an in-sample MAF ≥ 1%, to avoid errors in detection or mapping of
larger genetic variants in cross-ancestry comparisons, and models were adjusted for
age (if available), sex, probabilistic estimation of expression residuals (PEER) factors
(Stegle et al. 2012), genetic PCs, and per-dataset covariates. For each gene, the index
variant was identified by the minimal permutation p-value. eQTLs were called then on
lead variants if they passed a 5% false discovery rate (FDR) filter using Storey's q-value
(Storey 2002) methodology. Conditional eQTLs were identified via FastQTL's
permutation mode, by using each eQTL as an additional covariate in the model for a
given gene. The lead conditional eQTL for all genes were again FDR controlled at 5%,

and a maximum of 10 conditional steps were run. Finally, for a set of conditional eQTLs
for a given gene, a joint model was fit, and the final eQTL callset consisted of those
eQTLs whose joint model test passed a 5% FDR filter. eQTLs were only called for
genes classified as one of 'protein_coding', 'miRNA', 'IG_C_gene', 'IG_D_gene',
'IG_J_gene', 'IG_V_gene', 'TR_C_gene', 'TR_D_gene', 'TR_J_gene', 'TR_V_gene' as
defined in GENCODE (Harrow et al. 2012).
The second version of the 23andMe pipeline uses strand-aware RNA-seq quantification,
and the eQTLs were called using SusieR package (Wang et al. 2020) instead of
FastQTL, with expression PCs (selected with the elbow method) replacing PEER

10 factors in the modeling, and using the GENCODE v43 gene model (Supplementary
11 File Table 2). The pipeline natively generated credible sets with a set probability to
12 contain a SNP tagging the causal variant.

13

14 Genetic correlation of Long COVID with phenotypically similar traits

¹⁵ Though the exact biological mechanisms of Long COVID remain to be determined, it is
¹⁶ proposed that Long COVID is a consequence of the multi-system effect of acute-phase
¹⁷ COVID-19 infection (Thompson et al. 2023). The phenotypic clusters and
¹⁸ pathophysiology of Long COVID overlap with post-viral syndromes, dystonia, chronic
¹⁹ fatigue/MFS, endothelial dysfunction, and conditions associated with immune
²⁰ dysregulation and coagulopathies. To understand whether these phenotypic and
²¹ pathophysiological similarities have genetic underpinnings, we obtained the genetic
²² correlations between Long COVID and symptomatologically similar phenotypes in
²³ participants of European ancestry using LD score regression (Bulik-Sullivan et al. 2015).

We selected phenotypes if the phenotypes were available in the 23andMe database
and 1) the symptomatology of the phenotype overlapped with the symptoms of Long
COVID (chronic pain, chronic obstructive pulmonary disease, polymyalgia rheumatica,
chronic fatigue/myalgic encephalitis, fibromyalgia, Alzheimer's disease, polymyositis,
hypersensitivity pneumonitis, lupus, complex regional pain syndrome, asthma); and/or
2) the phenotype had known etiological precedent of viral illness (EBV-related illness
such as chronic fatigue syndrome/myalgic encephalitis, dysautonomia, multiple
sclerosis, Guillain-Barre syndrome, chronic EBV syndrome, immunodeficiency); and/or
3) phenotypes that have biological relevance and analytical associations with Long
COVID (depression, anxiety, diabetes, arrhythmias such as ventricular fibrillation and
ventricular tachycardia,clotting disorders such as arterial thrombosis, body-mass index,
lung cancer, myocardial infarction, fibromyalgia, and chronic fatigue) based on literature
review (Su et al. 2023; Thompson et al. 2023; Al-Aly, Xie, and Bowe 2021; Davis et al.
2023).

15

16 Mendelian randomization

¹⁷ Based on the estimates of genetic correlation between several chronic disease
¹⁸ phenotypes and Long COVID, we explored whether there was a potential causal role of
¹⁹ genetic liability to these conditions and Long COVID by conducting two sample
²⁰ Mendelian randomization (MR) using the *twosampleMR* package (Bowden et al. 2016)
²¹ in participants of European ancestry. The phenotypes that met all of the following
²² criteria were further considered for MR analysis: 1) more than 5,000 cases in their
²³ respective GWAS analysis; 2) genetic correlations met a statistical p-value threshold of

10.002/(0.05/26); 3) heritability of >1% as estimated by LD score regression; 4) 2 predisposing conditions that are associated with Long COVID in prior epidemiological 3 studies (Taylor et al. 2023; Naik et al. 2024; Ursini et al. 2021). Traits that met these 4 four conditions were chronic fatigue, fibromyalgia, and depression. A sub-cohort of 5 non-overlapping samples between each phenotype and Long COVID was derived and 6 GWAS analysis was performed in participants of European ancestry only. A genetic 7 instrument for each phenotype was derived using summary statistics. The index 8 variants from GWAS analysis (defined as above) that had minor allele frequency of $9 \ge 0.01$ were used to derive a genetic instrument for each phenotype. The estimates for 10 MR instruments were subsequently obtained from Long COVID GWAS conducted in 11 participants of European ancestry. We then fitted random effects inverse variance 12 weighted (IVW) models to obtain MR estimates for each non-COVID-19 phenotype. To 13 test the veracity of the findings, we used Steiger filtering and robust MR approaches 14 including weighted median and MR-Egger methods (Bowden et al. 2016; Bowden, 15 Davey Smith, and Burgess 2015; Hemani, Tilling, and Davey Smith 2017).

16

17 Sensitivity analyses

We repeated the above GWAS analytical approach for the Long COVID Impact phenotype to identify genetic signals for a more severe form of Long COVID. Additional sensitivity analyses explored the impact of acute SARS-CoV-2 infection severity (as assessed by hospitalization) because it is a known risk factor for Long COVID. To that end, we first further adjusted the association of index variants and Long COVID from the main GWAS for COVID-19 hospitalization at the time of acute SARS-CoV2 infection.

1 Second, using the same genetic instruments as in the main analysis, we evaluated MR 2 effects of chronic fatigue, fibromyalgia, and depression on COVID-19 hospitalization. 3 We further replicated our MR findings for Long COVID and COVID-19 hospitalization 4 using summary statistics for these phenotypes from COVID-19 Host Genetics Initiative. 5 In case of COVID-19 hospitalization, only multi-ancestry summary statistics for 6 COVID-19 hospitalization (Cases N = 16,512, Controls N = 71321) were available via 7 the HGI website (https://www.covid19hg.org/). Here, we first obtained the allele 8 information, and effect estimates for variants in each of our instruments from HGI 9 summary statistics. The variants were mapped using chromosome and position on hg38 10 genome build. Then we harmonized the allele information across 23andMe summary 11 statistics of each phenotype and Long COVID HGI data. The variants that did not align 12 for allele information were excluded from the instrument. We sought to replicate MR 13 findings for depression from two separate external MR instruments for depression 14 obtained using summary statistics from UK Biobank European participants (Howard et 15 al. 2018) and from meta-analysis of three largest studies on depression that included 16 UK BioBank, the 23andMe cohort, and the Psychiatric Genomics Consortium (Howard 17 et al. 2019). The effect estimates for Long COVID were obtained from European GWAS 18 conducted in this study. The depression phenotype in this UK BioBank was defined as 19 self-reported depressive symptoms, or primary or secondary diagnosis of depressive 20 mood disorder(ICD codes: F32—Single Episode Depression, F33—Recurrent 21 Depression, F34—Persistent mood disorders, F38—Other mood disorders and 22 F39—Unspecified mood disorders)(Howard et al. 2018, 2). The summary statistics and 23 MR instruments were accessed from publicly available GWAS catalog and

1 "MRCIEU/MRInstruments" R package respectively. We could not identify external
2 instruments for chronic fatigue and fibromyalgia because none of the existing GWAS
3 studies was sufficiently powered to identify genome-wide significant hits (Hajdarevic et 4 al. 2022; Zorina-Lichtenwalter et al. 2023; Backman et al. 2021).

5

6 RESULTS

7 The selection of the participants is represented in **Figure 1**. Among 332,638 research 8 participants who were eligible to participate in the Long COVID survey and reported 9 acute SARS-CoV2 infection, 64,384 participants reported to have experienced Long 10 COVID and 178,537 participants did not. After exclusions as described in Figure 1, we 11 had an analytical cohort of 54,390 cases and 124,777 controls. Characteristics for 12 unrelated cases and controls are summarized in **Table 1**, while characteristics by 13 ancestry group are tabulated in **Supplementary Table 1**. Most participants (78.9%) in 14 the analytical cohort were of European ancestry, followed by Latinx (16.6%) and 15 African-American (4.5%) ancestry. Cases were more likely to be females (66.7%), 16 non-tobacco users (37%), with a median age of 44 years [IQR=24] and mean BMI of 17 27.5 (SD=7.6). Compared to controls, cases were more likely to have high blood 18 pressure (OR= 1.52, 95% CI: 1.48, 1.56), depression (OR= 1.98, 95% CI: 1.92, 2.02), 19 cardiometabolic conditions (OR= 1.60, 95% CI: 1.56, 1.64), and autoimmune conditions 20 (OR= 1.55, 95% CI: 1.51, 1.59) after adjusting for age, sex, and ancestry. Among Long 21 COVID cases, 4.7% (vs 0.005% controls) were hospitalized during acute SARS-CoV2 22 infection and 8.0% (vs 0.01% controls) had severe respiratory disease. When asked

1 about the impact of Long COVID symptoms on daily life, 57.3% of Long COVID cases
2 reported moderate to severe impact.

3

4 GWAS of Long COVID

5 Using approximately 110 million imputed genetic variants, we identified three loci

6 associated with Long COVID in multi-ancestral analysis based on data from European,

7 African-American, and Latinx ancestry groups (Figure 2, Table 2).

8

9 *Genome-wide significant loci*: The top GWAS significant hit, (rs9273363; A/C with C 10 being the effect allele, OR= 1.06, 95% CI: 1.04, 1.08, p= 3.79×10^{-11}) was located in 11 chromosome 6 in the intergenic region spanning *HLA-DQA1* and *HLA-DQB1* 12 (**Supplemental Figure 1**). The effect sizes for rs9273363 were similar across all three 13 ancestries (p-value for heterogeneity across ancestries= 0.75). Further analysis of 14 specific *HLA* alleles and Long COVID showed that *HLA-DRB1**11:04 (OR=1.18, 95% 15 CI: 1.11, 1.24, p = 7.0 X 10⁻⁰⁹), HLA-C*07:01 (OR=0.94, 95%CI = 0.92, 0.96, p = 1.14 X 16 10⁻⁰⁸), HLA-B*08:01 (OR=0.93, 95%CI = 0.91, 0.95, p = 1.5 X 10⁻⁰⁸), and 17 HLA-DQA1*03:01 (OR=0.95, 95% CI = 0.93, 0.97, p = 4.1 X 10⁻⁰⁸) were significantly 18 associated with Long COVID. The effect sizes were similar across three ancestries 19 (**Supplementary Figure 2**).

20

21 The second most significant variant was observed at chromosome 9 in the ABO gene
22 (rs644234, G/T with T being the effect allele, OR= 0.95, 95% CI: 0.94, 0.97, p= 3.66 X
23 10⁻⁰⁹, p-value for heterogeneity across ancestries= 0.56) (Supplementary Figure 3).

Specifically, rs644234 is in linkage disequilibrium (LD) with a frame-shift variant
(rs8176719) within the ABO gene (European r2= 0.97, African-American r2= 0.44,
Latinx r2= 0.90). rs8176719 is one of the main variants determining the ABO blood
group and has been previously linked to COVID-19 susceptibility and severity (Bugert et
al. 2012; Severe Covid-19 GWAS Group et al. 2020; Shelton et al. 2021).

6

7 Another association was observed with rs2080090 (A/T with T being the effect allele;

8 OR= 0.95, 95% CI: 0.93, 0.97, p= 1.36X10⁻⁰⁸; p-value for heterogeneity across

9 ancestries=0.69) located in vicinity of the BPTF gene on chromosome 17

10 (Supplementary Figure 4). There are at least 3 plausible causal genes in the locus;
11 *BPTF*, *KPAN2*, and *C17orf58*. We observed eQTL signals in lymphoblast cells for a
12 variant in LD (rs12601921, r²=0.98, p= 4.31X10⁻⁸⁹) with rs2080090 for the *BPTF* gene
13 (Supplementary Table 2a). rs2080090 was also in LD with a coding variant, rs7502307
14 (r²=0.82), located at *C17orf58* (Supplementary Table 2b).

15

In European ancestry participants, the top associated SNP in this locus (rs78794747, A/T with T being the effect allele) was mapped to the intergenic region of *C17orf58* and *KPAN2*. rs78794747 is in high LD with multiple variants associated with gene
expression in CD14 monocytes, frontal cortex, and islets of Langerhans cells
(Supplementary Table 2c). The *C17orf58* gene has been associated with posterior
myocardial infarction (Norland et al. 2019). *KPAN2* encodes nuclear transport factor
importin α1, which is associated with viral suppression (Miyamoto et al. 2021). Previous
studies have shown that an accessory protein encoded by the SARS-CoV2 genome,

ORF6, binds to importin α1, enhancing viral propagation by inhibiting interferon type 1
 signaling (International HIV Controllers Study et al. 2010; Yuen et al. 2020; Miyamoto et
 al. 2021). Ancestry-specific GWAS hits are described further in Supplemental Results
 4 and Supplementary Table 3a-3c.

5

⁶ Associations between genome-wide significant variants and Long COVID persisted
⁷ upon adjusting for COVID-19 hospitalization (Supplementary Table 4a). When we
⁸ assessed the associations between these variants and COVID-19 hospitalization in our
⁹ study adjusting for age, age*sex, and principal components of ancestry, none of them
¹⁰ was significantly associated (Supplementary Table 4b).

11

12 In the summary statistics of the HGI Long COVID GWAS including 6,450 Cases and 13 46,208 controls, effect sizes of our index variants were similar. However, none of the 14 associations observed in our study was statistically significant in HGI data, which 15 consisted of almost 10x fewer cases (**Supplementary Table 5**). When we examined the 16 effect of rs9367106 near *FOXP4* (the significantly associated variant in HGI analyses of 17 Long COVID cases and population controls), the association in our study was not 18 statistically significant (p=0.57). Consistently with our observation, this variant was not 19 significantly associated with Long COVID in the HGI data (p=0.04) when the analyses 20 were limited to individuals who reported to be positive for SARS-CoV2.

21

22 GWAS of Long COVID Impact

1 In addition to *HLA-DQA1* and *HLA-DQB1* mentioned above, we identified one indel 2 variant on chromosome 6 in the intergenic region of *MICA* and *MICB* (OR = 0.91, 95% 3 CI: 0.88,0.94, p = 1.18×10^{-09} , p-heterogeneity across ancestries=0.61)

4 (Supplementary Figure 5, Supplementary Table 6). The variant, rs9281499, was in

5 LD with multiple variants that showed statistically significant pQTL signals for MICB

- 6 protein in blood plasma (Supplementary Figure 6, Supplementary Table 7a).
- 7 Additionally, rs9281499 is in LD with rs2596510 (r²=0.82) which is associated with

8 CYP21A2 expression in type1 (p=2.09X10⁻¹⁰) and type 2 (p=2.96 X 10⁻¹³) T-helper cells,

9 and CD4 T lymphocytes (2.45X10⁻¹⁰) (**Supplementary Table 7b**).

10

¹¹ There were two novel statistically significant loci in the multi-ancestry GWAS of Long
¹² COVID Impact phenotype. The top hit, rs58970548, is an indel variant located at the
¹³ intergenic region of *NMUR2* and *GRIA1* (OR= 0.94, 95% CI: 0.93, 0.96, p=4.27X10⁻⁸,
¹⁴ p-heterogeneity across ancestries=0.06). (Supplementary Figure 7). An additional
¹⁵ significant locus was observed at rs190759626 (G/T with T being the effect allele)
¹⁶ located at the intergenic region of *NUTM2A* and *NUTM2D* (Supplementary Figure 8)
¹⁷ on chromosome 10. Ancestry specific analyses are reported in Supplementary

18 Results.

19

20 Genetic Correlation with Similar Phenotypes

21

We identified 26 conditions in participants of European ancestry that met the criteria of
shared pathophysiology, similar clinical features, and previously published associations
with Long COVID Supplementary Table 8 (Sherif et al. 2023; Davis et al. 2023; Peter
et al. 2022; Cohen et al. 2022; Bull-Otterson et al. 2022; Davis et al. 2021; Ursini et al.

1 2021). We further limited the list of conditions to those with at least 5,000 cases 2 contributing to GWAS, p-value < 0.002 (0.05/26) for the genetic correlation with Long 3 COVID, and estimated heritability more than 1%. Overall, 13 phenotypes met the 4 criteria and are presented in **Figure 3.** The strongest genetic correlations were 5 observed between Long COVID and chronic pain (r_g =0.72,p=2.49X10⁻¹⁷⁰), chronic 6 fatigue (r_g =0.71,p=1.09X10⁻¹²⁰), and fibromyalgia (r_g =0.70,p=6.30X10⁻¹⁴²).

7

8 Mendelian Randomization

9 We investigated the potential causal role of three phenotypes (chronic fatigue, 10 fibromyalgia, and depression) with Long COVID through Mendelian randomization 11 (MR). We did not consider chronic pain due to its nonspecific definition in the 23 and Me 12 database. The genetic instrument for chronic fatigue included 186 SNPs (mean 13 F-statistic per SNP = 43.17), for fibromyalgia included 349 SNPs (mean F-statistic per 14 SNP=45.04), and for depression included 696 SNPs (mean F-statistic per SNP=53.8). 15 We found strong evidence of a potential causal effect to each of these three conditions 16 on Long COVID (chronic fatigue: OR=1.59 (95%CI: 1.51, 1.66), fibromyalgia: OR=1.54 17 (95%CI: 1.49, 1.60), and depression: OR=1.53 (95%CI: 1.46, 1.61); estimates from 18 IVW-MR). These effects persisted when employing robust MR approaches including 19 weighted median and MR Egger (Figure 4, Supplementary Figure 9, Supplementary 20 Table 9a). Steiger filtered and outlier filtered estimates (Supplementary Table 9a) were 21 similar to the respective IVW estimates for chronic fatigue and fibromyalgia. However, 22 for depression, the Steiger filtered estimates were closer to the null than IVW estimates. 23 The MR-Egger intercept for fibromyalgia was non-zero (-0.01, p = 0.01) with the

1 resultant MR-Egger causal estimate being stronger than IVW (Supplementary Table 2 9a). The Mendelian randomization findings were replicated and were in a direction 3 similar to our findings when the genetic instruments for the exposures derived from the 4 23andMe research cohort were applied to disease estimates derived from the Long ⁵ COVID HGI consortium (Supplementary Figure 10, Supplementary Table 10a). In the 6 Mendelian randomization analyses, the directions of effects for exposures applied to 7 COVID-19 hospitalization data from the COVID HGI consortium were also similar to our 8 findings (Supplementary Table 10b, Supplementary Figure 11). When we repeated 9 Mendelian randomization using the Long COVID Impact definition, the results were 10 consistent (Figure 4, Supplementary Figure 12, Supplementary Table 9b). MR 11 analysis showed evidence of genetic liability to chronic fatigue syndrome, fibromyalgia, 12 and depression leading to a higher risk of COVID-19 hospitalization (Figure 4, 13 Supplementary Figure 13, Supplementary Table 9c). Our results were also 14 consistent after using external instruments for depression derived solely from UK 15 Biobank GWAS which included 35 SNPs with a mean F statistic of 40.83, and 16 instruments derived from a meta-analysis of the UK BioBank, the 23andMe cohort, and 17 the Psychiatric Genomics Consortium including 87 SNPs with mean F statistic of 77.67 **18** (Supplementary Figure 14).

19

20 DISCUSSION

²¹ We report the largest GWAS of Long COVID to date among ancestrally diverse
²² participants with a history of SARS-CoV2 acute infection. Our top finding links the *HLA*²³ region, in particular the *HLA-DRB1**11:04 variant, to developing Long COVID. Additional

1 hits were observed in *ABO*, a previously reported severity locus, and a novel region
2 spanning the *BPTF- C17orf58- KPNA2* genes. Genetic correlation analysis showed
3 strong relationships between Long COVID and multiple chronic conditions, including
4 chronic fatigue, depression, and fibromyalgia. We identified strong evidence of a
5 potential causal effect of genetic liability to these conditions on the risk of Long COVID.

7 To date, only one study has reported GWAS findings of Long COVID, conducted by the 8 COVID-19 Host Genetics Initiative (HGI) (Lammi et al. 2023). The HGI study compared 9 6,450 Long COVID cases with 1,093,995 population controls from multiple countries 10 and identified a genome-wide significant association with rs9367106 in the FOXP4 11 locus. In contrast, our study has approximately a 7-fold larger number of cases, and is 12 contained within one cohort, increasing statistical power through sample size and 13 removing between-study heterogeneity, respectively. The association detected in the 14 COVID-19 HGI study was not significant in our analysis; cases and controls in our study 15 were both infected with SARS-CoV2, removing the effects of COVID-19 susceptibility by 16 design. The FOXP4 locus identified by HGI was functionally mapped to COVID-19 17 severity and lung function (Lammi et al. 2023; Wu et al. 2021; Pairo-Castineira et al. 18 2023), and potentially reflects the genetic signal relevant to acute infection susceptibility 19 and/or severity. In contrast, our analysis identified multiple loci (HLA-DRB1-20 HLA-DQA1, BPTF) that are independent of SARS-CoV-2 hospitalization, another 21 marker of COVID-19 severity, and instead are enriched for immune pathways. 22 Assessing the genome-wide significant hits of our study in the HGI data, the direction 23 and effect sizes for these variants were similar but did not meet statistical significance,

1 likely because our study was powered to pick up more subtle signals (Supplemental
2 Table 5).

3

⁴ We observed associations of Long COVID with variants in the *HLA* locus, highlighting
⁵ the role of immune mechanisms as postulated in earlier studies (Klein et al. 2023; Davis
⁶ et al. 2023; Augusto et al. 2023). *HLA* class II molecules including our top hit,
⁷ *HLA-DRB1*, play a critical role in the adaptive immune system by presenting foreign
⁸ peptide antigens to receptors on T lymphocytes, initiating an immune response on
⁹ exposure to viral antigens. Specifically, *HLA-DRB1*11* alleles have been previously
¹⁰ associated with asymptomatic SARS-CoV2 infections (Augusto et al. 2023; Ouedraogo
¹¹ et al. 2023). While the role of *HLA* variation in Long COVID has not been extensively
¹² studied, a prior smaller immunoprofiling study has found monocyte expression of MHC
¹³ class II (HLA-DR) to be higher among Long COVID cases compared to controls who
¹⁴ had experienced an acute SARS-CoV2 expression and recovered (Klein et al. 2023).
¹⁵ The discovery of the *HLA* association in a hypothesis-free analysis underscores the
¹⁶ importance of antigen presentation in the genetic susceptibility to Long COVID,
¹⁷ potentially informing future risk stratification and treatment approaches.

18

¹⁹ Our study contributes to the body of evidence in support of the role of *ABO* loci in
²⁰ SARS-CoV2 infection outcomes. Previous studies have identified *ABO* loci as
²¹ independently associated with COVID-19 susceptibility and severity (Shelton et al.
²² 2021; Severe Covid-19 GWAS Group et al. 2020; Pairo-Castineira et al. 2023; Zhao et
²³ al. 2021). While differential susceptibility to SARS-CoV2 infection was controlled for in

1 the design of our study, acute infection severity is a well-established risk factor for long 2 COVID (Tsampasian et al. 2023). The association between ABO variation and 3 COVID-19 outcomes is potentially driven by the ABO antibodies interfering with the 4 attachment of viral spike proteins to ACE2 receptors (Breiman, Ruven-Clouet, and Le ⁵ Pendu 2020; Guillon et al. 2008). Additionally, a proteomic analysis of rs657152 (LD r² 6 = 0.99 with our GWAS hit rs644234) within the ABO locus in a population-based cohort 7 identified proteins related to immune function such as IL-15 and STAT3 signaling 8 (Steffen et al. 2022). IL-15 has been proposed as a therapeutic strategy to improve 9 acute COVID-19 outcomes (Lu et al. 2022; National Library of Medicine (U.S.) 2020; 10 Kandikattu et al. 2020). Blood group subtypes encoded by ABO are also associated 11 with differential risk of thrombosis (Vasan et al. 2016), which represents another 12 potentially relevant etiologic mechanism linking ABO and Long COVID. In recent 13 studies, thrombo-inflammation has been reported as a clinical feature of Long COVID, 14 likely driven by dysregulated coagulation mechanisms in response to viral 15 antigen-antibody complexes (Cervia-Hasler et al. 2024).

16

¹⁷ We provide novel evidence establishing potential causal relationships between Long
¹⁸ COVID and genetically correlated conditions that share similar symptomologies, namely
¹⁹ chronic fatigue, depression, and fibromyalgia. The findings that genetic liability to
²⁰ chronic fatigue, depression and fibromyalgia also leads to a higher risk of hospitalization
²¹ for acute SARS-CoV-2 infection provides mechanistic insights. Prior studies have
²² reported depression can impair function of a broad range of immune cells (Drevets et al.
²³ 2022; Walther et al. 2022). While the relationship of chronic fatigue and fibromyalgia

1 with immune dysfunction is less clear, NK cell activity may be impaired among these 2 individuals (Brenu et al. 2012; Rivas et al. 2018; Verma et al. 2022), with altered NK cell 3 function also identified among patients with acute severe COVID-19 (Malengier-Devlies) 4 et al. 2022). Furthermore, there is growing evidence that immune and oxidative stress 5 pathways induce neuroaffective effects resulting in symptoms such as chronic fatigue 6 syndrome and depression (Al-Hakeim et al. 2023). A recent study found that Long 7 COVID and chronic fatigue syndrome share a common picture of impaired immune 8 response secondary to metabolic consequences of elevated oxidative stress in T 9 lymphocytes (Shankar et al. 2024). Thus the immune impact of chronic fatigue, 10 depression, and fibromyalgia potentially explains the well-documented higher risk of 11 Long COVID among individuals who experienced severe acute COVID-19. While the 12 immune pathway likely doesn't fully account for the increased risk of Long COVID, it 13 provides new information that could help identify subgroups of individuals that ought to 14 receive preventative measures such as ongoing vaccination to avoid severe acute 15 infection. Also notable from a translational perspective is the indel variant, rs58970548, 16 near the GRIA1 gene in the GWAS of the Long COVID impact phenotype. Though we 17 could not identify any functional signals at predetermined thresholds of significance 18 (r^2 >0.80 and p < 5 X 10⁻⁰⁸) in our datasets, the variants within 500kb and in linkage 19 disequilibrium (r²>0.5) of rs58970548 have been associated with various psychiatric 20 conditions (Parekh et al. 2018; Ismail et al. 2022; Chiesa et al. 2012). Specifically, 21 GRIA1 has been recently identified in brain proteome data as a potential drug target for 22 depression (Liu et al. 2023).

23

1 Our study has multiple strengths and limitations. First, this is the largest GWAS study of ² Long COVID to date that identified multiple etiologically relevant loci that help shed light 3 on Long COVID biology. Given the constellation of symptoms of Long COVID and their 4 varying severity at individual level (Davis et al. 2021), setting clinical trials for Long 5 COVID has been challenging in the absence of such data on biological mechanisms. By 6 providing evidence of immune function being a likely driving force for etiological tapestry 7 of Long COVID and associated conditions, there is an opportunity to reassess the 8 feasibility of repurposing existing therapeutic interventions planned in the Long COVID 9 trials. Second, the extensive database of 23andMe provided a unique opportunity to 10 study the shared genetic architecture of multiple phenotypes, linking Long COVID with 11 other disorders characterized by substantial unmet clinical need such as chronic fatigue 12 syndrome, depression, and fibromyalgia. Third, owing to the inclusion of more 13 genome-wide significant SNPs compared to prior studies (Lammi et al. 2023), the 14 genetic instruments explain a greater proportion of the genetic variability in the 15 exposures, potentially leading to more reliable MR estimates. Our MR estimates were 16 successfully replicated in an external dataset, lending further credence to our causal 17 conclusions. However, our findings must be interpreted in the context of several 18 limitations. The use of self-reported data enabled us to capture cases that may have 19 been overlooked due to diagnostic challenges surrounding Long COVID (Knuppel et al. 20 2023). Nevertheless, the self-reported data may also have introduced misclassification 21 bias due to subjectivity in grading of symptoms at the individual level. Additionally, 22 because participation in 23 and Me surveys is self-selected, our findings may not be 23 representative of the broader population. Furthermore, collider bias is a recognised

1 threat to the validity of COVID-19 studies (Griffith et al. 2020). However, the 696 genetic
2 variants comprising the MR instrument for depression were not associated with
3 participation into our study (p= 0.82) and almost all study participants responding to a
4 survey reported having experienced acute COVID-19, making both study respondents
5 to the Long Covid survey and study participation on the basis of previous acute
6 COVID-19 infection unlikely colliders, collectively alleviating selection bias concerns.

8 In summary, the largest multi-ancestry GWAS of Long COVID to date highlights new
9 biological mechanisms independent of COVID-19 susceptibility. Furthermore, we report
10 robust genetic correlations between Long COVID and a number of phenotypes with
11 similar symptoms, including chronic fatigue, fibromyalgia, and depression, as well as a
12 causal effect of liability to these conditions on Long COVID. Together, these findings can
13 help identify at-risk individuals for Long COVID, as well as provide novel insights that
14 support developing therapeutic options for both Long COVID and symptomatically
15 similar conditions.

1 ACKNOWLEDGEMENTS

² We would like to thank the research participants and employees of 23andMe for making
³ this work possible. The following members of the 23andMe Research Team contributed
⁴ to this study:

5 Stella Aslibekyan, Adam Auton, Elizabeth Babalola, Robert K. Bell, Jessica Bielenberg,

6 Ninad S. Chaudhary, Zayn Cochinwala, Sayantan Das, Emily DelloRusso, Payam

7 Dibaeinia, Sarah L. Elson, Nicholas Eriksson, Chris Eijsbouts, Teresa Filshtein, Pierre

8 Fontanillas, Davide Foletti, Will Freyman, Zach Fuller, Julie M. Granka, Chris German,

9 Éadaoin Harney, Alejandro Hernandez, Barry Hicks, David A. Hinds, M. Reza

10 Jabalameli, Ethan M. Jewett, Yunxuan Jiang, Sotiris Karagounis, Lucy Kaufmann, Matt

11 Kmiecik, Katelyn Kukar, Alan Kwong, Keng-Han Lin, Yanyu Liang, Bianca A. Llamas,

12 Aly Khan, Steven J. Micheletti, Matthew H. McIntyre, Meghan E. Moreno, Priyanka

13 Nandakumar, Dominique T. Nguyen, Jared O'Connell, Steve Pitts, G. David Poznik,

14 Alexandra Reynoso, Shubham Saini, Morgan Schumacher, Leah Selcer, Anjali J.

15 Shastri, Jingchunzi Shi, Suyash Shringarpure, Keaton Stagaman, Teague Sterling,

16 Qiaojuan Jane Su, Joyce Y. Tung, Susana A. Tat, Vinh Tran, Xin Wang, Wei Wang,

17 Catherine H. Weldon, Amy L. Williams, Peter Wilton.

24

25

26

27

28

1 2 AUTHOR INFORMATION

3 Affiliations:

4 23andMe, Inc:

- 5 Ninad S. Chaudhary, Catherine H. Weldon, Priyanka Nandakumar,
- 6 23andMe Research Team, Michael V. Holmes, Stella Aslibekyan

7

8 Author Contributions:

9 The 23andMe COVID-19 Team developed the recruitment and participant engagement

10 strategy and acquired and processed the data. N.S.C analyzed the data. N.S.C., P.A,

11 C.H.W, S.A, and M.V.H interpreted the data. N.S.C., S.A. and M.V.H. wrote the

12 manuscript. All authors participated in the preparation of the manuscript by reading and

13 commenting on the drafts before submission.

14			
15			
16			
17			
18			
19			
20			
21			
22			
23			
24			

1 ETHICS DECLARATIONS

2 Competing Interests

3 C.H.W, P.N, S,A, and M.V.H are current employees of 23andMe and hold stock or stock

4 options in 23andMe. N.S.C works as a postdoctoral fellow on the 23andMe Genetic

- 5 Epidemiology Team.

1 FIGURE LEGENDS:

2

³ Figure 1: Flowchart of 23andMe participants who participated in Long COVID ⁴ survey and were included in the analysis

5 47,364 participants were excluded if the symptoms are reported less than 3 months

6 from acute illness; 16,390 participants were excluded from the control group if they

7 reported some impact (selected option other than "not at all") on daily living activities

8 post acute illness. Participants of other ancestries (East Asian, South Asian, and Middle

9 Eastern) present in 23andMe research database were not included in the base cohort

10 due to insufficient sample size.



17

18

19

20

21

22

23

1 Figure 2: Manhattan plot of Long COVID among 23andMe participants

2 Manhattan plot depicts findings from the meta-analysis of three ancestral groups
3 (European, African American, and Latinx). X-axis represents chromosomal position for
4 each SNP. Y-axis represents negative log p-values based on logistic regression model
5 under the additive model. Statistically significant variants are highlighted in red. The
6 regions of associations are annotated with index variants.





Figure 3: Genetic correlation of Long COVID with chronic phenotypes in 23andMe participants of European ancestry

³ **Panel A:** Heat map showing genetic correlations between chronic phenotypes,

- 4 including Long COVID, obtained from LD Score regression.
- 5 Panel B: Bar plot represents genetic correlation values of chronic phenotypes and Long
- 6 COVID obtained from LD Score regression. X-axis shows a list of chronic phenotypes
- 7 plotted. Y-axis shows values of genetic correlation from 0 to 1. A complete list of
- 8 phenotypes are included in Supplementary Table 8.
- 9 RLS = Restless leg syndrome; Vtach = Ventricular tachycardia; DVT = Deep vein

10 thrombosis; dis. = disorders; COPD = Chronic obstructive pulmonary disease



- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24

Figure 4: Forest plot representing genetically predicted effects of chronic phenotypes using Mendelian randomization

³ Top row panel: Genetically predicted effects of chronic phenotypes on Long COVID

- 4 Middle row panel: *Genetically predicted effects of chronic phenotypes on Long COVID* 5 *impact*
- 6 Bottom row panel: Genetically predicted effects of chronic phenotypes on COVID-19 7 hospitalization
- 8 The estimates in the plot depict odds ratio and 95% confidence intervals. The genetic
- 9 instrument for chronic fatigue is derived using information from 186 SNPs (mean F
- 10 statistic = 43.17). The genetic instrument for chronic fatigue is derived using information
- 11 from 349 SNPs (mean F statistic = 45.04). The genetic instrument for depression is
- 12 derived using information from 696 SNPs (mean F statistic = 53.8). IVW = Inverse



	CASE	CONTROL
Ν	53,764	120,668
Demographics		
Age (median [IQR])	46.0[35.0,57.0]	43.0[33.0,57.0]
Female N (%)	41,324 (76.9)	74,981 (62.1)
Race N (%)		
African American	2,234 (4.2)	5,596 (4.6)
European	42,899 (79.8)	94,721 (78.5)
Latino	8,631 (16.1)	20,351 (16.9)
Education in years (mean (SD))	15.1 (2.4)	15.4 (2.6)
BMI (median [IQR])	28.4 [24.3,34.0]	27.3 [23.8,31.8]
Tobacco user N (%)	21,223 (39.5)	41,921 (35.7)
Two or more alcoholic drinks over past 2 weeks N (%)	10,114 (18.8)	28,733 (23.8)
Health Conditions		
High blood pressure N (%)	14,977 (27.8)	25,507 (21.1)
Depression N (%)	25,226 (46.9)	37,578 (31.1)
COPD N (%)	911 (1.7)	840 (0.01)
High total cholesterol N (%)	4,487 (8.3)	8,054 (6.7)
High triglyceride N (%)	3,207 (6.0)	5,444 (4.5)
Chronic Fatigue N (%)	3,980 (7.4)	1,866 (1.5)
Fibromyalgia N (%)	4,394 (8.2)	2,631 (2.2)
Cardiometabolic condition N (%)	23,566 (43.8)	41,115 (34.1)
Autoimmune N (%)	9,922 (18.4)	14,053 (11.6)
COVID-19+ and hospitalized N (%)	2,534 (4.7)	617 (0.005)
COVID-19+ and severe respiratory disease N (%)	4,282 (8.0)	1,198 (0.01)

Table 2: Estimates of genome-wide significant variants in meta-analysis of Long COVID GWAS

		-						
SNP	Chr	Position	Gene	Alleles	Effect allele	EAF	OR (95% CI)	P value
			HLA-DQA1[]HLA-DQB					
rs9273363	chr6	32658495	1	A/C	С	0.74	1.06(1.04,1.08)	3.79X10 ⁻¹¹
rs644234	chr9	133266804	[ABO]	G/T	Т	0.64	0.95(0.94,0.97)	3.66X10 ⁻⁰⁹
rs2080090	chr17	67832255	[BPTF]	A/T	Т	0.77	0.95(0.93,0.97)	1.36X10 ⁻⁰⁸
EAF = Effect allele frequency; OR (95% CI)=Odds ratio with 95% confidence interval; Chr = Chromosome								

1 REFERENCES

2

3 Al-Aly, Ziyad, Yan Xie, and Benjamin Bowe. 2021. "High-Dimensional Characterization

- 4 of Post-Acute Sequelae of COVID-19." *Nature* 594 (7862): 259–64.
- ⁵ https://doi.org/10.1038/s41586-021-03553-9.

6 Al-Hakeim, Hussein Kadhem, Haneen Tahseen Al-Rubaye, Dhurgham Shihab

7 Al-Hadrawi, Abbas F. Almulla, and Michael Maes. 2023. "Long-COVID Post-Viral

8 Chronic Fatigue and Affective Symptoms Are Associated with Oxidative Damage,

9 Lowered Antioxidant Defenses and Inflammation: A Proof of Concept and

10 Mechanism Study." *Molecular Psychiatry* 28 (2): 564–78.

11 https://doi.org/10.1038/s41380-022-01836-9.

12 Augusto, Danillo G., Lawton D. Murdolo, Demetra S. M. Chatzileontiadou, Joseph J.

13 Sabatino, Tasneem Yusufali, Noah D. Peyser, Xochitl Butcher, et al. 2023. "A

14 Common Allele of HLA Is Associated with Asymptomatic SARS-CoV-2 Infection."

15 *Nature* 620 (7972): 128–36. https://doi.org/10.1038/s41586-023-06331-x.

16 Backman, Joshua D., Alexander H. Li, Anthony Marcketta, Dylan Sun, Joelle Mbatchou,

17 Michael D. Kessler, Christian Benner, et al. 2021. "Exome Sequencing and

Analysis of 454,787 UK Biobank Participants." *Nature* 599 (7886): 628–34.

19 https://doi.org/10.1038/s41586-021-04103-z.

20 Bowden, Jack, George Davey Smith, and Stephen Burgess. 2015. "Mendelian

21 Randomization with Invalid Instruments: Effect Estimation and Bias Detection

through Egger Regression." *International Journal of Epidemiology* 44 (2):

23 512–25. https://doi.org/10.1093/ije/dyv080.

1 Bowden, Jack, George Davey Smith, Philip C. Haycock, and Stephen Burgess. 2016.

- ² "Consistent Estimation in Mendelian Randomization with Some Invalid
- 3 Instruments Using a Weighted Median Estimator." *Genetic Epidemiology* 40 (4):
- 4 304–14. https://doi.org/10.1002/gepi.21965.

5 Breiman, Adrien, Nathalie Ruvën-Clouet, and Jacques Le Pendu. 2020. "Harnessing the

- 6 Natural Anti-Glycan Immune Response to Limit the Transmission of Enveloped
- 7 Viruses Such as SARS-CoV-2." *PLoS Pathogens* 16 (5): e1008556.
- 8 https://doi.org/10.1371/journal.ppat.1008556.

9 Brenu, Ekua W., Mieke L. van Driel, Donald R. Staines, Kevin J. Ashton, Sharni L.

10 Hardcastle, James Keane, Lotti Tajouri, Daniel Peterson, Sandra B. Ramos, and

11 Sonya M. Marshall-Gradisnik. 2012. "Longitudinal Investigation of Natural Killer

12 Cells and Cytokines in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis."

Journal of Translational Medicine 10 (May):88.

14 https://doi.org/10.1186/1479-5876-10-88.

15 Bugert, Peter, Gabriele Rink, Katharina Kemp, and Harald Klüter. 2012. "Blood Group

ABO Genotyping in Paternity Testing." *Transfusion Medicine and Hemotherapy:*

17 Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und

Immunhamatologie 39 (3): 182–86. https://doi.org/10.1159/000339235.

19 Bulik-Sullivan, Brendan K., Po-Ru Loh, Hilary K. Finucane, Stephan Ripke, Jian Yang,

20 Schizophrenia Working Group of the Psychiatric Genomics Consortium, Nick

21 Patterson, Mark J. Daly, Alkes L. Price, and Benjamin M. Neale. 2015. "LD Score

22 Regression Distinguishes Confounding from Polygenicity in Genome-Wide

Association Studies." *Nature Genetics* 47 (3): 291–95.

1 https://doi.org/10.1038/ng.3211.

2 Bull-Otterson, Lara, Sarah Baca, Sharon Saydah, Tegan K. Boehmer, Stacey Adjei,

- 3 Simone Gray, and Aaron M. Harris. 2022. "Post–COVID Conditions Among Adult
- 4 COVID-19 Survivors Aged 18–64 and ≥65 Years United States, March
- 5 2020–November 2021." *MMWR. Morbidity and Mortality Weekly Report* 71 (21):
- 6 713–17. https://doi.org/10.15585/mmwr.mm7121e1.

7 Català, Martí, Núria Mercadé-Besora, Raivo Kolde, Nhung T H Trinh, Elena Roel,

8 Edward Burn, Trishna Rathod-Mistry, et al. 2024. "The Effectiveness of

9 COVID-19 Vaccines to Prevent Long COVID Symptoms: Staggered Cohort Study

10 of Data from the UK, Spain, and Estonia." *The Lancet Respiratory Medicine* 12

11 (3): 225–36. https://doi.org/10.1016/S2213-2600(23)00414-9.

12 Cervia-Hasler, Carlo, Sarah C. Brüningk, Tobias Hoch, Bowen Fan, Giulia Muzio, Ryan

13 C. Thompson, Laura Ceglarek, et al. 2024. "Persistent Complement

14 Dysregulation with Signs of Thromboinflammation in Active Long Covid." Science

15 (New York, N.Y.) 383 (6680): eadg7942.

16 https://doi.org/10.1126/science.adg7942.

17 Chaudhary, Ninad S, Catherine H Weldon, Priyanka Nandakumar, Janie Shelton,

18 23andMe Research Team, Michael V Holmes, and Stella Aslibekyan. 2024.

¹⁹ "Multi-Ancestry GWAS of Diarrhea during Acute SARS-CoV2 Infection Identifies

20 Multiple Novel Loci and Contrasting Etiological Roles of Irritable Bowel Syndrome

21 Subtypes." https://doi.org/10.1101/2024.04.03.24305274.

22 Cohen, Ken, Sheng Ren, Kevin Heath, Micah C. Dasmariñas, Karol Giuseppe Jubilo,

23 Yinglong Guo, Marc Lipsitch, and Sarah E. Daugherty. 2022. "Risk of Persistent

- and New Clinical Sequelae among Adults Aged 65 Years and Older during the
- 2 Post-Acute Phase of SARS-CoV-2 Infection: Retrospective Cohort Study." BMJ
- 3 (Clinical Research Ed.) 376 (February):e068414.
- 4 https://doi.org/10.1136/bmj-2021-068414.
- 5 COVID-19 Host Genetics Initiative. 2023. "A Second Update on Mapping the Human
- 6 Genetic Architecture of COVID-19." *Nature* 621 (7977): E7–26.
- 7 https://doi.org/10.1038/s41586-023-06355-3.
- 8 Craig, David W., Elizabeth Hutchins, Ivo Violich, Eric Alsop, J. Raphael Gibbs, Shawn
- 9 Levy, Madison Robison, et al. 2021. "RNA Sequencing of Whole Blood Reveals

10 Early Alterations in Immune Cells and Gene Expression in Parkinson's Disease."

11 *Nature Aging* 1 (8): 734–47. https://doi.org/10.1038/s43587-021-00088-6.

12 Davis, Hannah E., Gina S. Assaf, Lisa McCorkell, Hannah Wei, Ryan J. Low, Yochai

13 Re'em, Signe Redfield, Jared P. Austin, and Athena Akrami. 2021.

¹⁴ "Characterizing Long COVID in an International Cohort: 7 Months of Symptoms

and Their Impact." *eClinicalMedicine* 38 (August):101019.

16 https://doi.org/10.1016/j.eclinm.2021.101019.

17 Davis, Hannah E., Lisa McCorkell, Julia Moore Vogel, and Eric J. Topol. 2023. "Long

18 COVID: Major Findings, Mechanisms and Recommendations." *Nature Reviews*

Microbiology 21 (3): 133–46. https://doi.org/10.1038/s41579-022-00846-2.

20 Debebe, Bisrat J, Lies Boelen, James C Lee, IAVI Protocol C Investigators, Eduard J

Sanders, Omu Anzala, Anatoli Kamali, et al. 2020. "Identifying the Immune

22 Interactions Underlying HLA Class I Disease Associations." *eLife* 9

23 (April):e54558. https://doi.org/10.7554/eLife.54558.

1 Drev	ets, Wayne C., Gayle M. Wittenberg, Edward T. Bullmore, and Husseini K. Manji.
2	2022. "Immune Targets for Therapeutic Development in Depression: Towards
3	Precision Medicine." Nature Reviews Drug Discovery 21 (3): 224–44.
4	https://doi.org/10.1038/s41573-021-00368-1.
5 Dura	nd, Eric Y, Chuong B Do, Joanna L Mountain, and J. Michael Macpherson. 2014.
6	"Ancestry Composition: A Novel, Efficient Pipeline for Ancestry Deconvolution."
7	Preprint. Bioinformatics. https://doi.org/10.1101/010512.
8 Ferki	ngstad, Egil, Patrick Sulem, Bjarni A. Atlason, Gardar Sveinbjornsson, Magnus I.
9	Magnusson, Edda L. Styrmisdottir, Kristbjorg Gunnarsdottir, et al. 2021.
10	"Large-Scale Integration of the Plasma Proteome with Genetics and Disease."
11	Nature Genetics 53 (12): 1712–21. https://doi.org/10.1038/s41588-021-00978-w.
12 Ford	, Nicole D., Abraham Agedew, Alexandra F. Dalton, Jordan Singleton, Cria G.
13	Perrine, and Sharon Saydah. 2024. "Notes from the Field: Long COVID
14	Prevalence Among Adults — United States, 2022." MMWR. Morbidity and
15	Mortality Weekly Report 73 (6): 135–36.
16	https://doi.org/10.15585/mmwr.mm7306a4.
17 Franz	zén, Oscar, Raili Ermel, Ariella Cohain, Nicholas K. Akers, Antonio Di Narzo,
18	Husain A. Talukdar, Hassan Foroughi-Asl, et al. 2016. "Cardiometabolic Risk Loci
19	Share Downstream Cis- and Trans-Gene Regulation across Tissues and
20	Diseases." Science (New York, N.Y.) 353 (6301): 827–30.
21	https://doi.org/10.1126/science.aad6970.
22 Griffi	th, Gareth J., Tim T. Morris, Matthew J. Tudball, Annie Herbert, Giulia Mancano,
23	Lindsey Pike, Gemma C. Sharp, et al. 2020. "Collider Bias Undermines Our

1	Understanding of COVID-19 Disease Risk and Severity." Nature Communications
2	11 (1): 5749. https://doi.org/10.1038/s41467-020-19478-2.
3 GTE	x Consortium. 2020. "The GTEx Consortium Atlas of Genetic Regulatory Effects
4	across Human Tissues." Science (New York, N.Y.) 369 (6509): 1318–30.
5	https://doi.org/10.1126/science.aaz1776.
6 Guille	on, Patrice, Monique Clément, Véronique Sébille, Jean-Gérard Rivain, Chih-Fong
7	Chou, Nathalie Ruvoën-Clouet, and Jacques Le Pendu. 2008. "Inhibition of the
8	Interaction between the SARS-CoV Spike Protein and Its Cellular Receptor by
9	Anti-Histo-Blood Group Antibodies." Glycobiology 18 (12): 1085–93.
10	https://doi.org/10.1093/glycob/cwn093.
11 Hajda	arevic, Riad, Asgeir Lande, Jesper Mehlsen, Anne Rydland, Daisy D. Sosa, Elin B.
12	Strand, Olav Mella, et al. 2022. "Genetic Association Study in Myalgic
13	Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Identifies Several
14	Potential Risk Loci." Brain, Behavior, and Immunity 102 (May):362–69.
15	https://doi.org/10.1016/j.bbi.2022.03.010.
16 Harro	ow, Jennifer, Adam Frankish, Jose M. Gonzalez, Electra Tapanari, Mark Diekhans,
17	Felix Kokocinski, Bronwen L. Aken, et al. 2012. "GENCODE: The Reference
18	Human Genome Annotation for The ENCODE Project." Genome Research 22
19	(9): 1760–74. https://doi.org/10.1101/gr.135350.111.

20 Hemani, Gibran, Kate Tilling, and George Davey Smith. 2017. "Orienting the Causal

21 Relationship between Imprecisely Measured Traits Using GWAS Summary

22 Data." *PLoS Genetics* 13 (11): e1007081.

23 https://doi.org/10.1371/journal.pgen.1007081.

1 Howard, David M., Mark J. Adams, Toni-Kim Clarke, Jonathan D. Hafferty, Jude Gibson,

- 2 Masoud Shirali, Jonathan R. I. Coleman, et al. 2019. "Genome-Wide
- 3 Meta-Analysis of Depression Identifies 102 Independent Variants and Highlights
- 4 the Importance of the Prefrontal Brain Regions." *Nature Neuroscience* 22 (3):
- ⁵ 343–52. https://doi.org/10.1038/s41593-018-0326-7.

6 Howard, David M., Mark J. Adams, Masoud Shirali, Toni-Kim Clarke, Riccardo E.

7 Marioni, Gail Davies, Jonathan R. I. Coleman, et al. 2018. "Genome-Wide

8 Association Study of Depression Phenotypes in UK Biobank Identifies Variants in

9 Excitatory Synaptic Pathways." *Nature Communications* 9 (1): 1470.

10 https://doi.org/10.1038/s41467-018-03819-3.

11 International HIV Controllers Study, Florencia Pereyra, Xiaoming Jia, Paul J. McLaren,

Amalio Telenti, Paul I. W. de Bakker, Bruce D. Walker, et al. 2010. "The Major

13 Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation."

14 Science (New York, N.Y.) 330 (6010): 1551–57.

15 https://doi.org/10.1126/science.1195271.

16 Kandikattu, Hemanth Kumar, Sathisha Upparahalli Venkateshaiah, Sandeep Kumar,

and Anil Mishra. 2020. "IL-15 Immunotherapy Is a Viable Strategy for COVID-19."

18 Cytokine & Growth Factor Reviews 54 (August):24–31.

19 https://doi.org/10.1016/j.cytogfr.2020.06.008.

20 Kerimov, Nurlan, James D. Hayhurst, Kateryna Peikova, Jonathan R. Manning, Peter

21 Walter, Liis Kolberg, Marija Samoviča, et al. 2021. "A Compendium of Uniformly

22 Processed Human Gene Expression and Splicing Quantitative Trait Loci." *Nature*

23 Genetics 53 (9): 1290–99. https://doi.org/10.1038/s41588-021-00924-w.

1 Kettur	nen, Johannes, Taru Tukiainen, Antti-Pekka Sarin, Alfredo Ortega-Alonso, Emmi
2	Tikkanen, Leo-Pekka Lyytikäinen, Antti J. Kangas, et al. 2012. "Genome-Wide
3	Association Study Identifies Multiple Loci Influencing Human Serum Metabolite
4	Levels." Nature Genetics 44 (3): 269–76. https://doi.org/10.1038/ng.1073.
5 Klein,	Jon, Jamie Wood, Jillian R. Jaycox, Rahul M. Dhodapkar, Peiwen Lu, Jeff R.
6	Gehlhausen, Alexandra Tabachnikova, et al. 2023. "Distinguishing Features of
7	Long COVID Identified through Immune Profiling." Nature 623 (7985): 139–48.
8	https://doi.org/10.1038/s41586-023-06651-y.
9 Knupp	pel, Anika, Andy Boyd, John Macleod, Nishi Chaturvedi, and Dylan M Williams.
10	2023. "The Long COVID Evidence Gap: Comparing Self-Reporting and Clinical
11	Coding of Long COVID Using Longitudinal Study Data Linked to Healthcare
12	Records." https://doi.org/10.1101/2023.02.10.23285717.
13 Koolp	e, G. A., W. L. Nelson, T. L. Gioannini, L. Angel, N. Appelmans, and E. J. Simon.
14	1985. "Opioid Agonists and Antagonists. 6-Desoxy-6-Substituted Lactone,
15	Epoxide, and Glycidate Ester Derivatives of Naltrexone and Oxymorphone."
16	Journal of Medicinal Chemistry 28 (7): 949–57.
17	https://doi.org/10.1021/jm00145a018.
18 Lamm	i, Vilma, Tomoko Nakanishi, Samuel E. Jones, Shea J. Andrews, Juha
19	Karjalainen, Beatriz Cortés, Heath E. O'Brien, et al. 2023. "Genome-Wide
20	Association Study of Long COVID." Preprint. Genetic and Genomic Medicine.
21	https://doi.org/10.1101/2023.06.29.23292056.
22 Lappa	alainen, Tuuli, Michael Sammeth, Marc R. Friedländer, Peter A. C. 't Hoen, Jean
23	Monlong, Manuel A. Rivas, Mar Gonzàlez-Porta, et al. 2013. "Transcriptome and

1	Genome Sequencing Uncovers Functional Variation in Humans." Nature 501
2	(7468): 506–11. https://doi.org/10.1038/nature12531.
3 Ledfo	rd, Heidi. 2024. "Long COVID Is a Double Curse in Low-Income Nations — Here's
4	Why." <i>Nature</i> 625 (7993): 20–22. https://doi.org/10.1038/d41586-023-04088-x.
5 Lopez	z-Leon, Sandra, Talia Wegman-Ostrosky, Carol Perelman, Rosalinda Sepulveda,
6	Paulina A. Rebolledo, Angelica Cuapio, and Sonia Villapol. 2021. "More than 50
7	Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis."
8	Scientific Reports 11 (1): 16144. https://doi.org/10.1038/s41598-021-95565-8.
9 Lu, Ti	ng, Rui Ma, Wenjuan Dong, Kun-Yu Teng, Daniel S. Kollath, Zhiyao Li, Jinhee Yi,
10	et al. 2022. "Off-the-Shelf CAR Natural Killer Cells Secreting IL-15 Target Spike
11	in Treating COVID-19." Nature Communications 13 (1): 2576.
12	https://doi.org/10.1038/s41467-022-30216-8.
13 Miyan	noto, Yoichi, Yumi Itoh, Tatsuya Suzuki, Tomohisa Tanaka, Yusuke Sakai, Masaru
14	Koido, Chiaki Hata, et al. 2021. "SARS-CoV-2 ORF6 Disturbs Nucleocytoplasmic
15	Trafficking to Advance the Viral Replication."
16	https://doi.org/10.1101/2021.02.24.432656.
17 Naik,	Hiten, Karen C. Tran, John A. Staples, Roy H. Perlis, and Adeera Levin. 2024.
18	"Psychiatric Symptoms, Treatment Uptake, and Barriers to Mental Health Care
19	Among US Adults With Post-COVID-19 Condition." JAMA Network Open 7 (4):
20	e248481. https://doi.org/10.1001/jamanetworkopen.2024.8481.
21 Nation	nal Library of Medicine (U.S.). 2020. "A Phase I/II Study of Universal Off-the-Shelf
22	NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19. Identifier
23	NCT04324996." https://clinicaltrials.gov/ct2/show/NCT04324996.

1 Norla	nd, Kristjan, Gardar Sveinbjornsson, Rosa B. Thorolfsdottir, Olafur B. Davidsson,
2	Vinicius Tragante, Sridharan Rajamani, Anna Helgadottir, et al. 2019. "Sequence
3	Variants with Large Effects on Cardiac Electrophysiology and Disease." Nature
4	Communications 10 (1): 4803. https://doi.org/10.1038/s41467-019-12682-9.
5 Notar	te, Kin Israel, Jesus Alfonso Catahay, Jacqueline Veronica Velasco, Adriel
6	Pastrana, Abbygail Therese Ver, Flos Carmeli Pangilinan, Princess Juneire
7	Peligro, et al. 2022. "Impact of COVID-19 Vaccination on the Risk of Developing
8	Long-COVID and on Existing Long-COVID Symptoms: A Systematic Review."
9	eClinicalMedicine 53 (November):101624.
10	https://doi.org/10.1016/j.eclinm.2022.101624.
11 O'Ma	honey, Lauren L., Ash Routen, Clare Gillies, Winifred Ekezie, Anneka Welford,
12	Alexa Zhang, Urvi Karamchandani, et al. 2023. "The Prevalence and Long-Term
13	Health Effects of Long Covid among Hospitalised and Non-Hospitalised
14	Populations: A Systematic Review and Meta-Analysis." eClinicalMedicine 55
15	(January):101762. https://doi.org/10.1016/j.eclinm.2022.101762.
16 Onge	n, Halit, Alfonso Buil, Andrew Anand Brown, Emmanouil T. Dermitzakis, and
17	Olivier Delaneau. 2016. "Fast and Efficient QTL Mapper for Thousands of
18	Molecular Phenotypes." Bioinformatics 32 (10): 1479-85.
19	https://doi.org/10.1093/bioinformatics/btv722.
20 Pairo	-Castineira, Erola, Konrad Rawlik, Andrew D. Bretherick, Ting Qi, Yang Wu, Isar
21	Nassiri, Glenn A. McConkey, et al. 2023. "GWAS and Meta-Analysis Identifies 49
22	Genetic Variants Underlying Critical COVID-19." Nature 617 (7962): 764–68.
23	https://doi.org/10.1038/s41586-023-06034-3.

1 Peter, Raphael S, Alexandra Nieters, Hans-Georg Kräusslich, Stefan O Brockmann, Siri Göpel, Gerhard Kindle, Uta Merle, Jürgen M Steinacker, Dietrich Rothenbacher, 2 and Winfried V Kern. 2022. "Post-Acute Sequelae of Covid-19 Six to 12 Months 3 after Infection: Population Based Study." BMJ, October, e071050. 4 https://doi.org/10.1136/bmj-2022-071050. 5 6 Qiu, Chengxiang, Shizheng Huang, Jihwan Park, YoSon Park, Yi-An Ko, Matthew J. Seasock, Joshua S. Bryer, et al. 2018. "Renal Compartment-Specific Genetic 7 Variation Analyses Identify New Pathways in Chronic Kidney Disease." Nature 8 Medicine 24 (11): 1721-31. https://doi.org/10.1038/s41591-018-0194-4. 9 10 Raj, Towfigue, Katie Rothamel, Sara Mostafavi, Chun Ye, Mark N. Lee, Joseph M. Replogle, Ting Feng, et al. 2014. "Polarization of the Effects of Autoimmune and 11 Neurodegenerative Risk Alleles in Leukocytes." Science (New York, N.Y.) 344 12 (6183): 519–23. https://doi.org/10.1126/science.1249547. 13 14 Rivas, Jose Luis, Teresa Palencia, Guerau Fernández, and Milagros García. 2018. "Association of T and NK Cell Phenotype With the Diagnosis of Myalgic 15 Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)." Frontiers in 16 17 Immunology 9 (May):1028. https://doi.org/10.3389/fimmu.2018.01028. 18 Robertson, McKaylee M, Saba A Qasmieh, Sarah G Kulkarni, Chloe A Teasdale, Heidi 19 E Jones, Margaret McNairy, Luisa N Borrell, and Denis Nash. 2023. "The Epidemiology of Long Coronavirus Disease in US Adults." *Clinical Infectious* 20 Diseases 76 (9): 1636–45. https://doi.org/10.1093/cid/ciac961. 21 22 Severe Covid-19 GWAS Group, David Ellinghaus, Frauke Degenhardt, Luis Bujanda, 23 Maria Buti, Agustín Albillos, Pietro Invernizzi, et al. 2020. "Genomewide

Association Study of Severe Covid-19 with Respiratory Failure." *The New*

- 2 England Journal of Medicine 383 (16): 1522–34.
- ³ https://doi.org/10.1056/NEJMoa2020283.

4 Shankar, Vishnu, Julie Wilhelmy, Ellis J. Curtis, Basil Michael, Layla Cervantes, Vamsee

5 A. Mallajosyula, Ronald W. Davis, et al. 2024. "Oxidative Stress Is a Shared

6 Characteristic of ME/CFS and Long COVID."

7 https://doi.org/10.1101/2024.05.04.592477.

8 Shelton, Janie F., Anjali J. Shastri, Chelsea Ye, Catherine H. Weldon, Teresa

9 Filshtein-Sonmez, Daniella Coker, Antony Symons, et al. 2021. "Trans-Ancestry

10 Analysis Reveals Genetic and Nongenetic Associations with COVID-19

11 Susceptibility and Severity." *Nature Genetics* 53 (6): 801–8.

12 https://doi.org/10.1038/s41588-021-00854-7.

13 Sherif, Zaki A., Christian R. Gomez, Thomas J. Connors, Timothy J. Henrich, William

Brian Reeves, and RECOVER Mechanistic Pathway Task Force. 2023.

¹⁵ "Pathogenic Mechanisms of Post-Acute Sequelae of SARS-CoV-2 Infection

16 (PASC)." *eLife* 12 (March):e86002. https://doi.org/10.7554/eLife.86002.

17 Soriano, Joan B., Srinivas Murthy, John C. Marshall, Pryanka Relan, Janet V. Diaz, and

18 WHO Clinical Case Definition Working Group on Post-COVID-19 Condition.

19 2022. "A Clinical Case Definition of Post-COVID-19 Condition by a Delphi

20 Consensus." *The Lancet. Infectious Diseases* 22 (4): e102–7.

21 https://doi.org/10.1016/S1473-3099(21)00703-9.

22 Steffen, Brian T, James S Pankow, Pamela L Lutsey, Ryan T Demmer, Jeffrey R

23 Misialek, Weihua Guan, Logan T Cowan, Josef Coresh, Faye L Norby, and

1	Weihong Tang. 2022. "Proteomic Profiling Identifies Novel Proteins for Genetic
2	Risk of Severe COVID-19: The Atherosclerosis Risk in Communities Study."
3	Human Molecular Genetics 31 (14): 2452–61.
4	https://doi.org/10.1093/hmg/ddac024.
5 Stegle	e, Oliver, Leopold Parts, Matias Piipari, John Winn, and Richard Durbin. 2012.
6	"Using Probabilistic Estimation of Expression Residuals (PEER) to Obtain
7	Increased Power and Interpretability of Gene Expression Analyses." Nature
8	Protocols 7 (3): 500–507. https://doi.org/10.1038/nprot.2011.457.
9 Store	y, John D. 2002. "A Direct Approach to False Discovery Rates." Journal of the
10	Royal Statistical Society Series B: Statistical Methodology 64 (3): 479–98.
11	https://doi.org/10.1111/1467-9868.00346.
12 Su, Si	izhen, Yimiao Zhao, Na Zeng, Xiaoxing Liu, Yongbo Zheng, Jie Sun, Yi Zhong, et
13	al. 2023. "Epidemiology, Clinical Presentation, Pathophysiology, and
14	Management of Long COVID: An Update." Molecular Psychiatry, July.
15	https://doi.org/10.1038/s41380-023-02171-3.
16 Taque	et, Maxime, Quentin Dercon, Sierra Luciano, John R. Geddes, Masud Husain, and
17	Paul J. Harrison. 2021. "Incidence, Co-Occurrence, and Evolution of
18	Long-COVID Features: A 6-Month Retrospective Cohort Study of 273,618
19	Survivors of COVID-19." PLoS Medicine 18 (9): e1003773.
20	https://doi.org/10.1371/journal.pmed.1003773.
21 Taylor	r, Krystyna, Matthew Pearson, Sayoni Das, Jason Sardell, Karolina Chocian, and
22	Steve Gardner. 2023. "Genetic Risk Factors for Severe and Fatigue Dominant
23	Long COVID and Commonalities with ME/CFS Identified by Combinatorial

1 Analysis." *Journal of Translational Medicine* 21 (1): 775.

2 https://doi.org/10.1186/s12967-023-04588-4.

³ Thompson, Ryan C., Nicole W. Simons, Lillian Wilkins, Esther Cheng, Diane Marie Del

- 4 Valle, Gabriel E. Hoffman, Carlo Cervia, et al. 2023. "Molecular States during
- 5 Acute COVID-19 Reveal Distinct Etiologies of Long-Term Sequelae." Nature
- 6 *Medicine* 29 (1): 236–46. https://doi.org/10.1038/s41591-022-02107-4.

7 Tian, Chao, Bethann S. Hromatka, Amy K. Kiefer, Nicholas Eriksson, Suzanne M.

- 8 Noble, Joyce Y. Tung, and David A. Hinds. 2017. "Genome-Wide Association and
- 9 HLA Region Fine-Mapping Studies Identify Susceptibility Loci for Multiple
- 10 Common Infections." *Nature Communications* 8 (1): 599.
- 11 https://doi.org/10.1038/s41467-017-00257-5.

12 Tran, Viet-Thi, Elodie Perrodeau, Julia Saldanha, Isabelle Pane, and Philippe Ravaud.

- 13 2023. "Efficacy of First Dose of Covid-19 Vaccine versus No Vaccination on
- 14 Symptoms of Patients with Long Covid: Target Trial Emulation Based on

15 ComPaRe e-Cohort." *BMJ Medicine* 2 (1): e000229.

16 https://doi.org/10.1136/bmjmed-2022-000229.

17 Tsampasian, Vasiliki, Hussein Elghazaly, Rahul Chattopadhyay, Maciej Debski, Thin Kyi

18 Phyu Naing, Pankaj Garg, Allan Clark, Eleana Ntatsaki, and Vassilios S.

19 Vassiliou. 2023. "Risk Factors Associated With Post-COVID-19 Condition: A

- 20 Systematic Review and Meta-Analysis." JAMA Internal Medicine 183 (6):
- 21 566–80. https://doi.org/10.1001/jamainternmed.2023.0750.

22 Ursini, Francesco, Jacopo Ciaffi, Luana Mancarella, Lucia Lisi, Veronica Brusi, Carlotta

23 Cavallari, Martina D'Onghia, et al. 2021. "Fibromyalgia: A New Facet of the

1	Post-COVID-19 Syndrome Spectrum? Results from a Web-Based Survey." RMD
2	Open 7 (3): e001735. https://doi.org/10.1136/rmdopen-2021-001735.
3 Vasar	n, Senthil K., Klaus Rostgaard, Ammar Majeed, Henrik Ullum, Kjell-Einar Titlestad,
4	Ole B. V. Pedersen, Christian Erikstrup, et al. 2016. "ABO Blood Group and Risk
5	of Thromboembolic and Arterial Disease: A Study of 1.5 Million Blood Donors."
6	Circulation 133 (15): 1449–57; discussion 1457.
7	https://doi.org/10.1161/CIRCULATIONAHA.115.017563.
8 Verm	a, Vivek, Gillian L. Drury, Marc Parisien, Ayşe N. Özdağ Acarli, Tho-Alfakar
9	Al-Aubodah, Anastasia Nijnik, Xia Wen, et al. 2022. "Unbiased Immune Profiling
10	Reveals a Natural Killer Cell-Peripheral Nerve Axis in Fibromyalgia." Pain 163
11	(7): e821–36. https://doi.org/10.1097/j.pain.000000000002498.
12 Walth	er, Andreas, Anne Mackens-Kiani, Julian Eder, Maik Herbig, Christoph Herold,
13	Clemens Kirschbaum, Jochen Guck, Lucas Daniel Wittwer, Katja Beesdo-Baum,
14	and Martin Kräter. 2022. "Depressive Disorders Are Associated with Increased
15	Peripheral Blood Cell Deformability: A Cross-Sectional Case-Control Study
16	(Mood-Morph)." Translational Psychiatry 12 (1): 150.
17	https://doi.org/10.1038/s41398-022-01911-3.
18 Wang	, Gao, Abhishek Sarkar, Peter Carbonetto, and Matthew Stephens. 2020. "A
19	Simple New Approach to Variable Selection in Regression, with Application to
20	Genetic Fine Mapping." Journal of the Royal Statistical Society Series B:
21	Statistical Methodology 82 (5): 1273–1300. https://doi.org/10.1111/rssb.12388.
22 Wellc	ome Trust Case Control Consortium, Julian B. Maller, Gilean McVean, Jake
23	Byrnes, Damjan Vukcevic, Kimmo Palin, Zhan Su, et al. 2012. "Bayesian

1	Refinement of Association Signals for 14 Loci in 3 Common Diseases." Nature
2	Genetics 44 (12): 1294–1301. https://doi.org/10.1038/ng.2435.
3 Whita	ker, Matthew, Joshua Elliott, Marc Chadeau-Hyam, Steven Riley, Ara Darzi,
4	Graham Cooke, Helen Ward, and Paul Elliott. 2022. "Persistent COVID-19
5	Symptoms in a Community Study of 606,434 People in England." Nature
6	Communications 13 (1): 1957. https://doi.org/10.1038/s41467-022-29521-z.
<mark>7</mark> Wu, P	eng, Lin Ding, Xiaodong Li, Siyang Liu, Fanjun Cheng, Qing He, Mingzhong Xiao,
8	et al. 2021. "Trans-Ethnic Genome-Wide Association Study of Severe
9	COVID-19." Communications Biology 4 (1): 1034.
10	https://doi.org/10.1038/s42003-021-02549-5.
11 Yuen,	Chun-Kit, Joy-Yan Lam, Wan-Man Wong, Long-Fung Mak, Xiaohui Wang, Hin
12	Chu, Jian-Piao Cai, et al. 2020. "SARS-CoV-2 Nsp13, Nsp14, Nsp15 and Orf6
13	Function as Potent Interferon Antagonists." Emerging Microbes & Infections 9
14	(1): 1418–28. https://doi.org/10.1080/22221751.2020.1780953.
15 Zhang	g, Jingning, Diptavo Dutta, Anna Köttgen, Adrienne Tin, Pascal Schlosser, Morgan
16	E. Grams, Benjamin Harvey, et al. 2022. "Plasma Proteome Analyses in
17	Individuals of European and African Ancestry Identify Cis-pQTLs and Models for
18	Proteome-Wide Association Studies." Nature Genetics 54 (5): 593-602.
19	https://doi.org/10.1038/s41588-022-01051-w.
20 Zhao,	Jiao, Yan Yang, Hanping Huang, Dong Li, Dongfeng Gu, Xiangfeng Lu, Zheng
21	Zhang, et al. 2021. "Relationship Between the ABO Blood Group and the
22	Coronavirus Disease 2019 (COVID-19) Susceptibility." Clinical Infectious
23	Diseases: An Official Publication of the Infectious Diseases Society of America

1 73 (2): 328–31. https://doi.org/10.1093/cid/ciaa1150.

2 Zheng, X., J. Shen, C. Cox, J. C. Wakefield, M. G. Ehm, M. R. Nelson, and B. S. Weir.

- 3 2014. "HIBAG--HLA Genotype Imputation with Attribute Bagging." The
- 4 *Pharmacogenomics Journal* 14 (2): 192–200. https://doi.org/10.1038/tpj.2013.18.

5 Zorina-Lichtenwalter, Katerina, Carmen I. Bango, Lukas Van Oudenhove, Marta Čeko,

- 6 Martin A. Lindquist, Andrew D. Grotzinger, Matthew C. Keller, Naomi P.
- 7 Friedman, and Tor D. Wager. 2023. "Genetic Risk Shared across 24 Chronic Pain
- 8 Conditions: Identification and Characterization with Genomic Structural Equation
- 9 Modeling." *Pain* 164 (10): 2239–52.
- 10 https://doi.org/10.1097/j.pain.00000000002922.
- 11